Table 2.
Alectinib treatment for ALK+ IMT
| Authors | Age (year) | Sex | ALK fusion | ALK inhibitor | Line | Response | PFS (months) | Other treatment |
|---|---|---|---|---|---|---|---|---|
| Gros et al. [20] | 39 | F | RNABP2-ALK | Alectinib | 1st | CR | 6+ | |
| Rao et al. [61] | 21 | F | NUMA1-ALK | Alectinib | 2nd | Near CR | 13+ | Crizotinib (1st) |
| Kyi et al. [65] | 68 | F | TNS1-ALK | Alectinib | 2nd | PR | 12 | Crizotinib (1st), ceritinib (3rd), lorlatinib (4th) |
| Sunga et al. [67] | 30 | F | SQSTM1–ALK | Alectinib | 1st | PR | 36+ | |
| Wang et al. [99] | 42 | F | PRRC2B-ALK | Alectinib | 2nd | PR | 5.5 | Crizotinib (1st), ceritinib (3rd), lorlatinib (4th) |
| Zhang et al. [100] | 22 | M | RRBP1-ALK | Alectinib | 2nd | SD | 5 | Crizotinib (1st), ceritinib (3rd) |
| 60 | F | TNS1-ALK | Alectinib | 2nd | SD | 3 | Crizotinib (1st) | |
| Yuan et al. [109] | 18 | F | NR | Alectinib | 3rd | NR | 8 | Crizotinib (1st), ceritinib (2nd), lorlatinib (4th) |
| Takeyasu et al. [124] | 14 | M | NR | Alectinib | 2nd | CR | 44.2 | Adriamycin and ifosfamide (1st) |
| 52 | M | CTLC-ALK | Alectinib | 2nd | PR | 11.5 | Adriamycin/ifosfamide (1st), ceritinib (3rd), pazopanib (4th), eribulin (5th) | |
| Saiki et al. [125] | 26 | M | EML4-ALK | Alectinib | 1st | PR | 4.4+ | |
| Honda et al. [126] | 46 | M | SQSTM1–ALK | Alectinib | 1st | PR | 12+ | |
| Han et al. [127] | 56 | F | EML4-ALK | Alectinib | 1st | PR | 16+ | |
| Spafford et al. [128] | 29 | F | NR | Alectinib | 2nd | PD | 0 | Crizotinib (1st) |
| Fujiki et al .[129] | 6 | F | FN1-ALK | Alectinib | 1st | PR | 2 |
M male, F female, SD stable disease, PR partial response, CR complete response, NR not reported, ALK anaplastic lymphoma kinase, PRRC2B proline rich coiled-coil 2B, TNS1 tensin 1, RRBP1 ribosome binding protein 1, CTLC Clathrin heavy chain, EML4 echinoderm microtubule-associated protein-like 4, SQSTM1 sequestosome 1, TPM3 tropomyosin 3, NUMA1 nuclear mitotic apparatus protein 1, FN1 fibronectin 1, RNABP2 RNA binding protein 2